Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：2

作者：

Herrera, Alex F. ^{[1
]}

Bartlett, Nancy L. ^{[2
]}

Ramchandren, Radhakrishnan ^{[3
]}

Vose, Julie M. ^{[4
]}

Moskowitz, Alison J. ^{[5
]}

Feldman, Tatyana A. ^{[6
]}

LaCasce, Ann S. ^{[7
]}

Ansell, Stephen M. ^{[8
]}

Moskowitz, Craig H. ^{[5
]}

Fenton, Keenan ^{[9
]}

Kato, Kazunobu ^{[10
]}

Fong, Abraham ^{[9
]}

Advani, Ranjana H. ^{[11
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol HCT, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA

[3] Karmanos Canc Inst, Detroit, MI 48202 USA

[4] Univ Nebraska Med Ctr, Dept Hematol Oncol, Omaha, NE 68198 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07601 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Mayo Clin, Rochester, MN 55905 USA

[9] Seattle Genet Inc, Bothell, WA 98021 USA

[10] Bristol Myers Squibb Co, Princeton, NJ 08543 USA

[11] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

来源：

关键词：

D O I：

10.1182/blood.V128.22.1105.1105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1105

引用

页数：5